title: Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H.
abstract: We describe a case of severe reactivation of occult hepatitis B virus infection in a 49-year-old man, who was treated with high doses of chlorambucil for a Binet stage A B-cell chronic lymphocytic leukemia (B-CLL). The patient was initially treated with lamivudine and subsequently with lamivudine and adefovir dipivoxil combination therapy to control viral replication and allow for long-term anti-cancer chemotherapy with alemtuzumab (Campath-1H), which was introduced to rescue for a B-CLL relapse. During 20 months of anti-HBV therapy, ALT and HBV-DNA levels progressively declined and B-CLL was successfully kept under control by long-term alemtuzumab administration.
authors.affiliation: Hematology 1-Bone Marrow Transplantation Unit and the IRCCS Fondazione Ospedale Maggiore, University of Milan, via Francesco Sforza 35, 20122 Milan, Italy. agostino.cortelezzi@unimi.it
authors.forename: Agostino
authors.initials: A
authors.lastname: Cortelezzi
authors.forename: Mauro
authors.initials: M
authors.lastname: Viganò
authors.forename: Vittorio R
authors.initials: VR
authors.lastname: Zilioli
authors.forename: Norma N
authors.initials: NN
authors.lastname: Fantini
authors.forename: Maria C
authors.initials: MC
authors.lastname: Pasquini
authors.forename: Giorgio Lambertenghi
authors.initials: GL
authors.lastname: Deliliers
authors.forename: Massimo
authors.initials: M
authors.lastname: Colombo
authors.forename: Pietro
authors.initials: P
authors.lastname: Lampertico
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006509:Hepatitis B / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage* / Q000627:therapeutic use; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications*; D063065:Organophosphonates / Q000008:administration & dosage* / Q000627:therapeutic use; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D063065:Organophosphonates; D019259:Lamivudine; D000074323:Alemtuzumab; C053001:adefovir; D000225:Adenine